Recursion Pharmaceuticals' stock rises on heavy trading volume, with investors eyeing its AI-designed cancer drug REC-3565 ...

If it can bounce back and generate solid returns in the next five years, now is about as good a time as any to invest in the ...

Recursion Pharmaceuticals (RXRX) is up 17.9%, or 93c to $6.17. Published first on TheFly – the ultimate source for real-time, market-moving ...

We came across a bullish thesis on Recursion Pharmaceuticals, Inc. on Emil Hartela Investing’s Substack by Emil. In this article, we will summarize the bulls’ thesis on RXRX. Recursion Pharmaceuticals ...

Next year’s Java release is slated to include a performance boost for the G1 garbage collector and opt-in support for HTTP/3. The Applets API is on the chopping block. Java Development Kit (JDK) 26, a ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $4.98, demonstrating a +1.32% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...

Oracle’s Java team sat down with me last week for a fast-moving briefing on Java 25 and the broader direction of the platform. The headline: JDK 25 is an LTS release, the second on Oracle’s new ...

Recursion Pharmaceuticals (RXRX) closed at $4.77 in the latest trading session, marking a -1.24% move from the prior day. This change lagged the S&P 500's 0.47% gain on the day. Meanwhile, the Dow ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Recursion Pharmaceuticals, Inc. is one of them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a ...